Vanta Bioscience Limited, initially established as Vanta Bioscience Private Limited in April 2016, converted to a public limited company in March 2017. The company specializes in preclinical activities, offering risk assessment services for evaluating the safety of active pharmaceutical ingredients, excipients, and pharmaceutical impurities. As a center of excellence for GLP toxicology, Vanta Bioscience conducts both in vitro and in vivo toxicology studies for clients worldwide, adhering to various regulatory standards.
With state-of-the-art facilities in Gummidipundi, Chennai, acquired from Kemin Industries, Vanta Bioscience conducts extensive toxicology research across chemicals, pharmaceuticals, cosmetics, and agrochemicals. In September 2017, the company issued public shares to raise Rs 7.56 Crore. Furthermore, Vanta Bioscience expanded its operations with the acquisition of subsidiaries Vanta Clinical Research Limited and Vayam Research Solutions Limited in 2018-19, enhancing its capabilities in preclinical proof-of-concept studies for novel pharmaceuticals.
